Group 1 - BillionToOne officially listed on NASDAQ with an opening stock price surge of 81.57%, reaching a market capitalization of nearly $4.8 billion [1] - The IPO price was set at $60, with the stock opening at $100 and peaking at $123.45 during trading, indicating strong investor interest [1] - The company raised $273 million by issuing 4.55 million shares, with the offering size increased by 20% within regulatory limits [1] Group 2 - BillionToOne specializes in non-invasive prenatal testing (NIPT) and tumor blood testing based on single-molecule sequencing technology [2] - The company reported an 82% year-over-year revenue growth and a doubling of gross profit for the first half of the year, showcasing strong commercialization capabilities [2] - The successful IPO of BillionToOne is seen as a significant signal of recovery in the IPO market, particularly for high-growth medical technology companies [2]